Tumor Necrosis factor receptor

Fc fusion protein does not improve septic shock and may increase mortality in human

Autores

  • Álvaro Nagib Atallah Universidade Federal de São Paulo

Downloads

Não há dados estatísticos.

Biografia do Autor

Álvaro Nagib Atallah, Universidade Federal de São Paulo

MD, PhD, MSc Department of Internal Medicine, Escola Paulista de Medicina Chairman, Editor, São Paulo Medical Journal.

Referências

Fisher CJ, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc Fusion Protein. N Engl J Med 1996;334:1697-702.

Trace KJ, Beuther B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.

Feinberg B, Kurzrock R, Talpaz M, Blicks M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988;6:1328-34.

Beutler B, Milsark IW, Ceramio AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.

Walsh CJ, Sugerman HJ, Mullen PG, et al. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg 1992;127:138-45.

Downloads

Publicado

1996-05-05

Como Citar

1.
Atallah Álvaro N. Tumor Necrosis factor receptor: Fc fusion protein does not improve septic shock and may increase mortality in human. Sao Paulo Med J [Internet]. 5º de maio de 1996 [citado 16º de outubro de 2025];114(3):1151. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/2001

Edição

v. 114 n. 3 (1996)

Seção

Editorial

Licença

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.